Advertisement
Singapore markets closed
  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     
  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • FTSE 100

    7,831.15
    -45.90 (-0.58%)
     
  • Bitcoin USD

    64,706.75
    +2,998.39 (+4.86%)
     
  • CMC Crypto 200

    1,329.69
    +17.07 (+1.32%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • Dow

    37,775.38
    +22.07 (+0.06%)
     
  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     
  • Gold

    2,395.30
    -2.70 (-0.11%)
     
  • Crude Oil

    82.28
    -0.45 (-0.54%)
     
  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     
  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     
  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

Here's How Moderna Turned a Profit in Q1 Despite Its Sales Declining by 69%

Here's How Moderna Turned a Profit in Q1 Despite Its Sales Declining by 69%

Moderna (NASDAQ: MRNA) surprised investors last quarter when it didn't incur a loss despite a significant drop in sales. For the first three months of 2023, Moderna's revenue totaled just under $1.9 billion, which is just a fraction of the $6.1 billion it reported in the same period last year. Meanwhile, its operating expenses, totaling $2.2 billion, rose by more than 21%.